Mass Production System at Medytox Osong Plant No. 3

"Establishing a Foundation to Meet Diverse Clinical Needs"

Numeco, a subsidiary of Medytox, announced on June 22, 2026, that it had received domestic product approval from the Ministry of Food and Drug Safety on June 19 for its botulinum toxin product “Newlux 200 Units (Clostridium botulinum toxin type A).”


Newlux is a freeze-dried botulinum toxin formulation developed by Numeco through a technology transfer of next-generation toxin candidates from Medytox. The product employs the latest manufacturing processes to enhance production yield and quality. Notably, it is the first 900kDa formulation to exclusively use non-animal origin culture media during bacterial cultivation, thereby eliminating the risk of contamination from animal-derived components. Additionally, by reducing chemical treatment steps, it minimizes denaturation of the active neurotoxin protein.

Numeco Receives Domestic Product Approval for Botulinum Toxin “Newlux 200 Units” View original image

Newlux 200 Units shares the same formulation, efficacy, and indications as the 100 Units approved domestically in 2023, but contains twice the amount of the active ingredient. This product will be manufactured at Medytox’s Chungbuk Osong Plant No. 3.


Numeco aims to strengthen its market presence and competitiveness by ensuring a stable supply of Newlux 200 Units, which will enable more effective responses to the diverse procedural environments and needs in clinical settings. The availability of multiple dosage options is also expected to enhance convenience for medical professionals and improve procedural efficiency.



A Numeco representative stated, “With this 200 Units domestic product approval, we have established a foundation for enhancing our global regulatory approval and export competitiveness. We will continue to elevate the brand value of Newlux based on our differentiated quality competitiveness and research and development capabilities.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing